Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 56
Filter
1.
Early Interv Psychiatry ; 15(5): 1136-1145, 2021 10.
Article in English | MEDLINE | ID: mdl-33058435

ABSTRACT

AIM: The aim of the present study was to detect factors associated with duration of untreated illness (DUI) in bipolar disorder (BD). METHOD: A total of 1575 patients were selected for the purposes of the study. Correlation analyses were performed to analyse the relation between DUI and quantitative variables. The length of DUI was compared between groups defined by qualitative variables through one-way analyses of variance or Kruskal-Wallis's tests according to the distribution of the variable. Linear multivariable regressions were used to find the most parsimonious set of variables independently associated with DUI: to this aim, qualitative variables were inserted with the numeric code of their classes by assuming a proportional effect moving from one class to another. RESULTS: An inverse significant correlation between length of DUI and time between visits in euthymic patients was observed (r = -.52, P < .001). DUI resulted to be longer in patients with: at least one lifetime marriage/partnership (P = .009), a first psychiatric diagnosis of major depressive disorder or substance abuse (P < .001), a depressive polarity of first episode (P < .001), no lifetime psychotic symptoms (P < .001), BD type 2 (P < .001), more lifetime depressive/hypomanic episodes (P < .001), less lifetime manic episodes (P < .001), presence of suicide attempts (P = .004), depressive episodes (P < .001), hypomanic episodes (P = .004), hospitalizations (P = .011) in the last year. CONCLUSIONS: Different factors resulted to increase the length of DUI in a nationwide sample of bipolar patients. In addition, the DUI was found to show a negative long-term effect in terms of more suicidal behaviour, more probability of hospitalization and depressive/hypomanic episodes.


Subject(s)
Bipolar Disorder , Depressive Disorder, Major , Psychotic Disorders , Bipolar Disorder/epidemiology , Depressive Disorder, Major/diagnosis , Depressive Disorder, Major/epidemiology , Humans , Suicidal Ideation , Suicide, Attempted
2.
Clin Pharmacokinet ; 58(9): 1219-1220, 2019 Sep.
Article in English | MEDLINE | ID: mdl-31214940

ABSTRACT

The pharmacokinetics of CRP was tested in small short-term studies in both healthy volunteers and in subjects with schizophrenia, with similar results [242].

3.
Aust N Z J Psychiatry ; 53(8): 772-781, 2019 08.
Article in English | MEDLINE | ID: mdl-30658550

ABSTRACT

OBJECTIVE: Psychotic versus non-psychotic patients with bipolar disorder have been traditionally associated with different unfavorable clinical features. In this study on bipolar Italian patients, we aimed to compare clinical and demographic differences between psychotic and non-psychotic individuals, exploring clinical factors that may favor early diagnosis and personalized treatment. METHODS: A total of 1671 patients (males: n = 712 and females: n = 959; bipolar type 1: n = 1038 and bipolar type 2: n = 633) from different psychiatric departments were compared according to the lifetime presence of psychotic symptoms in terms of socio-demographic and clinical variables. Chi-square tests for qualitative variables and Student's t-tests for quantitative variables were performed for group comparison, and a multivariable logistic regression was performed, considering the lifetime psychotic symptoms as dependent variables and socio-demographic/clinical characteristics as independent variables. RESULTS: Psychotic versus non-psychotic bipolar subjects resulted to: be more frequently unemployed (p < 0.01) and never married/partnered (p < 0.01); have an earlier age at onset (p < 0.01); more frequently receive a first diagnosis different from a mood disorder (p < 0.01); have a shorter duration of untreated illness (p < 0.01); have a more frequently hypomanic/manic prevalent polarity (p < 0.01) and a prevalent manic-depressive type of cycling (p < 0.01); present a lower lifetime number of depressive episodes (p < 0.01), but have more manic episodes (p < 0.01); and less insight (p < 0.01) and more hospitalizations in the last year (p < 0.01). Multivariable regression analysis showed that psychotic versus non-psychotic bipolar patients received more frequently a first diagnosis different from bipolar disorder (odds ratio = 0.64, 95% confidence interval = [0.46, 0.90], p = 0.02) or major depressive disorder (odds ratio = 0.66, 95% confidence interval = [0.48, 0.91], p = 0.02), had more frequently a prevalent manic polarity (odds ratio = 1.84, 95% confidence interval = [1.14, 2.98], p < 0.01) and had a higher number of lifetime manic episodes (more than six) (odds ratio = 8.79, 95% confidence interval = [5.93, 13.05], p < 0.01). CONCLUSION: Lifetime psychotic symptoms in bipolar disorder are associated with unfavorable socio-demographic and clinical features as well as with a more frequent initial misdiagnosis.


Subject(s)
Bipolar Disorder/epidemiology , Depressive Disorder, Major/epidemiology , Psychotic Disorders/epidemiology , Adult , Age of Onset , Bipolar Disorder/psychology , Depressive Disorder, Major/complications , Depressive Disorder, Major/psychology , Female , Humans , Italy/epidemiology , Logistic Models , Male , Middle Aged , Multivariate Analysis , Psychotic Disorders/complications , Psychotic Disorders/psychology , Risk Factors , Time Factors
4.
Aust N Z J Psychiatry ; 53(5): 413-423, 2019 05.
Article in English | MEDLINE | ID: mdl-30545239

ABSTRACT

BACKGROUND: Elderly bipolar disorder (BD) and behavioural variant of frontotemporal dementia (bvFTD) may exhibit similar symptoms and both disorders are characterized by selective abnormalities in cortical and subcortical regions that are associated with cognitive and emotional impairments. We aimed to investigate common and distinct neural substrates of BD and bvFTD by coupling, for the first time, magnetic resonance imaging (MRI) and positron emission tomography (PET) techniques. METHODS: 3-Tesla MRI and 18 fluorodeoxyglucose-PET scans were acquired for 16 elderly BD patients, 23 bvFTD patients with mild cognitive impairments and 68 healthy controls (48 for PET and 20 for MRI analyses). RESULTS: BD and bvFTD patients exhibit a different localization of grey matter reductions in the lateral prefrontal cortex, with the first group showing grey matter decrease in the ventrolateral prefrontal cortex and the latter group showing grey matter reductions in the dorsolateral prefrontal cortex as well as unique grey matter and metabolic alterations within the orbitofrontal cortex. The bvFTD group also displayed unique volumetric shrinkage in regions within the temporo-parietal network together with greater metabolic impairments within the temporal cortex and more extensive volumetric and metabolic abnormalities within the limbic lobe. Finally, while the BD group showed greater grey matter volumes in caudate nucleus, bvFTD subjects displayed lower metabolism. CONCLUSION: This MRI-PET study explored, for the first time to the best of our knowledge, structural and functional abnormalities in bvFTD and elderly BD patients, with the final aim of identifying the specific biological signature of these disorders, which might have important implications not only in prevention but also in differential diagnosis and treatment.


Subject(s)
Aging , Bipolar Disorder , Cerebral Cortex , Frontotemporal Dementia , Gray Matter , Magnetic Resonance Imaging , Nerve Net , Positron-Emission Tomography , Aged , Aging/metabolism , Aging/pathology , Bipolar Disorder/diagnostic imaging , Bipolar Disorder/metabolism , Bipolar Disorder/pathology , Cerebral Cortex/diagnostic imaging , Cerebral Cortex/metabolism , Cerebral Cortex/pathology , Female , Frontotemporal Dementia/diagnostic imaging , Frontotemporal Dementia/metabolism , Frontotemporal Dementia/pathology , Gray Matter/diagnostic imaging , Gray Matter/metabolism , Gray Matter/pathology , Humans , Male , Multimodal Imaging , Nerve Net/diagnostic imaging , Nerve Net/metabolism , Nerve Net/pathology
5.
Bipolar Disord ; 21(2): 151-158, 2019 03.
Article in English | MEDLINE | ID: mdl-30506616

ABSTRACT

OBJECTIVES: Psychotic symptoms are a common feature in bipolar disorder (BD), especially during manic phases, and are associated with a more severe course of illness. However, not all bipolar subjects experience psychosis during the course of their illness, and this difference often guides assessment and pharmacological treatment. The aim of the present study is to elucidate, for the first time, the FDG uptake dysfunctions associated with psychosis in BD patients with and without a history of past psychotic symptoms, through a positron emission tomography (PET) approach. METHODS: Fifty BD patients with lifetime psychotic symptoms, 40 BD patients without lifetime psychotic symptoms and 27 healthy controls (HC) were recruited and underwent an 18F-FDG-PET session. RESULTS: Compared to HC, BD subjects shared common FDG uptake deficits in several brain areas, including insula, inferior temporal gyrus and middle occipital gyrus. Moreover, we found that BD patients with a history of past psychotic symptoms had a unique FDG uptake alteration in the right fusiform gyrus compared to both BD patients without lifetime psychotic symptoms and HC (all P < 0.01, cFWE corrected). CONCLUSIONS: Overall, our results suggest that FDG uptake alterations in brain regions involved in emotion regulation are a key feature of BD, regardless the presence of past psychosis. Finally, we demonstrated that the FDG uptake reduction in fusiform gyrus is associated with the presence of past psychotic symptoms in BD, ultimately leading towards the idea that the fusiform gyrus might be considered a putative biomarker of psychosis.


Subject(s)
Bipolar Disorder/diagnostic imaging , Bipolar Disorder/metabolism , Psychotic Disorders/metabolism , Adult , Bipolar Disorder/psychology , Brain/diagnostic imaging , Brain/physiopathology , Emotions , Female , Fluorodeoxyglucose F18 , Humans , Male , Middle Aged , Positron-Emission Tomography/methods , Psychotic Disorders/diagnostic imaging , Psychotic Disorders/psychology , Radiopharmaceuticals
6.
Clin Pharmacokinet ; 57(12): 1493-1528, 2018 12.
Article in English | MEDLINE | ID: mdl-29915922

ABSTRACT

Therapeutic drug monitoring studies have generally concentrated on controlling compliance and avoiding side effects by maintaining long-term exposure to minimally effective blood concentrations. The rationale for using therapeutic drug monitoring in relation to second-generation antipsychotics is still being discussed at least with regard to the real clinical utility, but there is evidence that it can improve efficacy, especially when patients do not respond or develop side effects using therapeutic doses. Furthermore, drug plasma concentration determinations can be of some utility in medico-legal problems. This review concentrates on the clinical pharmacokinetic data related to clozapine, risperidone, paliperidone, olanzapine, quetiapine, amisulpride, ziprasidone, aripiprazole, sertindole, asenapine, iloperidone, lurasidone, brexpiprazole and cariprazine and briefly considers the main aspects of their pharmacodynamics. Optimal plasma concentration ranges are proposed for clozapine, risperidone, paliperidone and olanzapine because the studies of quetiapine, amisulpride, asenapine, iloperidone and lurasidone provide only limited information and there is no direct evidence concerning ziprasidone, aripiprazole, sertindole, brexpiprazole and cariprazine: the few reported investigations need to be confirmed and extended.


Subject(s)
Antipsychotic Agents/administration & dosage , Drug Monitoring/methods , Animals , Antipsychotic Agents/adverse effects , Antipsychotic Agents/pharmacokinetics , Dose-Response Relationship, Drug , Humans , Medication Adherence
7.
Riv Psichiatr ; 53(6): 290-298, 2018.
Article in English | MEDLINE | ID: mdl-30667395

ABSTRACT

INTRODUCTION: Duration of untreated illness (DUI) has been increasingly investigated as a predictor of clinical outcome and course in different psychiatric disorders. To date, however, there are no tools for measuring this variable. Our group developed the Psychopathological Onset and Latency to Treatment Questionnaire (POLT-Q), focused on the onset of psychiatric disorders. Aim of this study was to assess the reproducibility and manageability of POLT-Q. METHODS: Fifty consecutive in- and out-patients aged 16-65 with different DSM-5 psychiatric disorders were recruited. Two raters were present during the interview: one of them administered the POLT-Q to the patient and both independently completed the questionnaire. Collected values were compared using Cohen's Kappa test and McNemar test. RESULTS: 62.5% of the replies showed a 100% consistency between the two raters. In the 6.25% the agreement was <95%. For all the replies, the K coefficient was >0.8, a high degree of agreement. DISCUSSION AND CONCLUSION: The POLT-Q assesses variables related to the psychopathological onset and first pharmacological treatment and, according to present findings, it represents a convenient, reliable and standardised measure for DUI. Further studies on larges sample are needed to confirm our preliminary results.


Subject(s)
Mental Disorders/therapy , Self Report , Time-to-Treatment/statistics & numerical data , Adolescent , Adult , Aged , Female , Forms as Topic , Humans , Male , Middle Aged , Reproducibility of Results , Young Adult
8.
Neuropsychobiology ; 75(1): 32-38, 2017.
Article in English | MEDLINE | ID: mdl-28803247

ABSTRACT

BACKGROUND: In the last decades, there has been increasing interest in investigating the role of the vermis in bipolar disorder (BD), especially because of its involvement in cognitive processes. The main aims of this study were to explore the integrity of the vermis and elucidate the role of demographic and clinical variables on vermis volumes in BD patients, stratified according to gender. METHODS: T1-weighted images were obtained for 38 BD patients and 38 healthy controls using a 1.5-T MRI scanner. Images were analyzed with a PC workstation with BRAINS2 software on a Linux system. Anatomical regions were traced manually from a blinded operator, with respect to subject identity and other clinical variables. RESULTS: The direct comparison between the 2 groups showed no significant gray matter differences in vermis volumes. Interestingly, vermis volumes were significantly inversely associated with chronological age and age of BD onset, particularly in male subjects. CONCLUSIONS: Our study provides evidence of the impact of aging on the vermis in BD, potentially related to earlier and faster gender-related neurodegenerative phenomena occurring during the progression of the disease.


Subject(s)
Aging , Bipolar Disorder/complications , Cerebral Cortex/diagnostic imaging , Disease Progression , Magnetic Resonance Imaging , Sex Characteristics , Adult , Female , Humans , Image Processing, Computer-Assisted , Male , Middle Aged , Psychiatric Status Rating Scales , Statistics as Topic
9.
World J Psychiatry ; 7(2): 128-132, 2017 Jun 22.
Article in English | MEDLINE | ID: mdl-28713691

ABSTRACT

Increasing evidence shows that cognitive impairment and brain abnormalities can appear early in the first episodes of schizophrenia, but it is currently debated how brain changes can correlate with clinical presentation of schizophrenic patients. Of note, this report describes the case of a young schizophrenic male presenting parietal magnetic resonance/positron emission tomography abnormalities and cognitive impairment, documented by specific neuropsychological tests. In our knowledge only few studies have investigated if neuropsychological abnormalities could be concomitant with both structural and functional neuroimaging. This case shows that impairment in specific cognitive domains is associated with structural/functional brain abnormalities in the corresponding brain areas (frontal and parietal lobes), supporting the hypothesis of disconnectivity, involving a failure to integrate anatomical and functional pathways. Future research would define the role of cognitive impairment and neurodegeneration in psychiatric nosography and, in particular, their role in the early phases of illness and long-term outcome of schizophrenic patients.

10.
J Child Psychol Psychiatry ; 58(12): 1290-1300, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28714195

ABSTRACT

BACKGROUND: Attention deficit and hyperactivity disorder (ADHD) is a developmental disorder characterized by an inability to sustain attention, activity levels and impulse control, and, according to the latest studies, the prevalence is about 8% and in some countries less than 1%. Currently, it is well-known that complications during the perinatal period have significant implications on child's physical and mental health. Purpose of the present paper is to review the literature about the association between perinatal complications and future risk of an ADHD diagnosis. METHODS: A research in the main database sources has been conducted to obtain a systematic review on the perinatal risk factors of ADHD. RESULTS: Among perinatal complications, available data indicate low birth weight (LBW) (Cohen's d effect size range: 0.31-1.64-small effect size) and preterm birth (PB) (range d: 0.41-0.68) as the most important factors associated with a future diagnosis of ADHD. CONCLUSIONS: PB and LBW children should be carefully monitored for an early diagnosis of ADHD limiting the impact of the disease in life span. A systematic review focusing on these risk factors have not been published until now, in the next future preventive strategies should be developed in order to minimize ADHD onset.


Subject(s)
Apgar Score , Asphyxia Neonatorum/complications , Attention Deficit Disorder with Hyperactivity/etiology , Infant, Low Birth Weight , Infant, Premature , Obstetric Labor Complications , Female , Humans , Infant, Newborn , Pregnancy
11.
J Affect Disord ; 219: 25-30, 2017 09.
Article in English | MEDLINE | ID: mdl-28505499

ABSTRACT

BACKGROUND: Transcranial direct current stimulation (tDCS) is a promising neuromodulation intervention for poor-responding or refractory depressed patients. However, little is known about predictors of response to this therapy. The present study aimed to analyze clinical predictors of response to tDCS in depressed patients. METHODS: Clinical data from 3 independent tDCS trials on 171 depressed patients (including unipolar and bipolar depression), were pooled and analyzed to assess predictors of response. Depression severity and the underlying clinical dimensions were measured using the Hamilton Depression Rating Scale (HDRS) at baseline and after the tDCS treatment. Age, gender and diagnosis (bipolar/unipolar depression) were also investigated as predictors of response. Linear mixed models were fitted in order to ascertain which HDRS factors were associated with response to tDCS. RESULTS: Age, gender and diagnosis did not show any association with response to treatment. The reduction in HDRS scores after tDCS was strongly associated with the baseline values of "Cognitive Disturbances" and "Retardation" factors, whilst the "Anxiety/Somatization" factor showed a mild association with the response. LIMITATIONS: Open-label design, the lack of control group, and minor differences in stimulation protocols. CONCLUSIONS: No differences in response to tDCS were found between unipolar and bipolar patients, suggesting that tDCS is effective for both conditions. "Cognitive disturbance", "Retardation", and "Anxiety/Somatization", were identified as potential clinical predictors of response to tDCS. These findings point to the pre-selection of the potential responders to tDCS, therefore optimizing the clinical use of this technique and the overall cost-effectiveness of the psychiatric intervention for depressed patients.


Subject(s)
Depressive Disorder, Major/therapy , Transcranial Direct Current Stimulation/methods , Adult , Anxiety/physiopathology , Bipolar Disorder/physiopathology , Bipolar Disorder/therapy , Cognitive Dysfunction/physiopathology , Control Groups , Cost-Benefit Analysis , Depressive Disorder, Major/physiopathology , Female , Humans , Male , Middle Aged , Psychiatric Status Rating Scales , Treatment Outcome
12.
Aust N Z J Psychiatry ; 51(10): 1010-1019, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28410561

ABSTRACT

OBJECTIVE: Anatomical alterations in the superior temporal gyrus have been consistently reported in patients with schizophrenia, and they have mostly been linked to positive symptoms, including hallucinations and thought disorders. The superior temporal gyrus is considered one of the most asymmetric and lateralized structure of the human brain, and the process of lateralization seems to vary according to gender in the normal population. However, although it has been consistently suggested that patients with schizophrenia did not show normal brain lateralization in several regions, only few studies investigated it in the superior temporal gyrus and its sub-regions considering the effects of gender. In this context, the aim of this study was to evaluate sexual dimorphism in superior temporal gyrus volumes in a sample of patients with schizophrenia compared to age- and gender-matched healthy controls. METHODS: A total of 72 right/left-handed males (40 schizophrenia patients and 32 healthy controls) and 45 right/left-handed females (18 schizophrenia patients and 27 healthy controls) underwent clinical evaluation and a 1.5T magnetic resonance imaging scan. Gray and white matter volumes of regions of interest within the superior temporal gyrus were manually detected, including the Heschl's gyrus and the planum temporale. RESULTS: Female patients with schizophrenia presented a reduction in left planum temporale gray matter volumes ( F = 4.58, p = 0.03) and a lack of the normal planum temporale asymmetry index ( t = 0.27; p = 0.79) compared to female controls ( t = 5.47; p = 0.001). No differences were found between males for any volumes or laterality indices. Finally, in female patients with schizophrenia, Heschl's gyrus gray and white matter volumes negatively correlated with positive symptoms ( r = -0.56, p = 0.01). CONCLUSION: Our results showed that sexual dimorphism plays a key role on planum temporale in schizophrenia, underlining the importance of gender as a modulator of brain morphology and lateralization of schizophrenia.


Subject(s)
Gray Matter/pathology , Schizophrenia/pathology , Sex Characteristics , Temporal Lobe/pathology , White Matter/pathology , Adult , Female , Gray Matter/diagnostic imaging , Humans , Magnetic Resonance Imaging , Male , Schizophrenia/diagnostic imaging , Schizophrenia/physiopathology , Temporal Lobe/diagnostic imaging , White Matter/diagnostic imaging
13.
Psychiatr Danub ; 29(1): 24-27, 2017 Mar.
Article in English | MEDLINE | ID: mdl-28291970

ABSTRACT

Available data support a contribution of both neurodevelopmental and neurodegenerative factors in the etiology of schizophrenia (SCH) and bipolar disorder (BD). Of note, one of the most important issue of the current psychiatric research is to identify the specific factors that contribute to impaired brain development and neurodegeneration in SCH and BD, and especially how these factors alter normal brain development and physiological aging process. Our hypothesis is that only specific damages, taking place in precise brain development stages, are associated with future SCH /BD onset and that neurodegeneration consists of an acceleration of brain aging after SCH /BD onset. In support of our hypothesis, the results of the present narrative mini-review shows as neurodevelopmental damages generally contribute to neuropsychiatric syndromes (e.g. hypothyroidism or treponema pallidum), but only some of them are specifically associated with adult SCH and BD (e.g. toxoplasma or substance abuse), particularly if they happen in specific stages of brain development. On the other hand, cognitive impairment and brain changes, associated with long duration of SCH /BD, look like what happens during aging: memory, executive domains and prefrontal cortex are implicated both in aging and in SCH /BD progression. Future research will explore possible validity of this etiological model for SCH and BD.


Subject(s)
Aging/physiology , Bipolar Disorder/physiopathology , Brain/physiopathology , Neurodegenerative Diseases/physiopathology , Neurodevelopmental Disorders/physiopathology , Prenatal Exposure Delayed Effects/physiopathology , Prenatal Exposure Delayed Effects/psychology , Schizophrenia/physiopathology , Schizophrenic Psychology , Adolescent , Adult , Bipolar Disorder/diagnosis , Bipolar Disorder/psychology , Child , Child, Preschool , Environmental Exposure/adverse effects , Female , Humans , Infant , Infant, Newborn , Male , Neurodegenerative Diseases/diagnosis , Neurodegenerative Diseases/psychology , Neurodevelopmental Disorders/diagnosis , Neurodevelopmental Disorders/psychology , Pregnancy , Prenatal Exposure Delayed Effects/diagnosis , Schizophrenia/diagnosis , Young Adult
14.
J Geriatr Psychiatry Neurol ; 30(3): 162-169, 2017 May.
Article in English | MEDLINE | ID: mdl-28351199

ABSTRACT

Psychiatric symptoms in patients with frontotemporal dementia (FTD) are highly prevalent and may complicate clinical management of these patients. Purpose of the present article is to present and discuss available data about the pharmacological treatment of psychiatric symptoms in patients with FTD. A research in the main database sources has been conducted to obtain an overview of the pharmacological management of psychiatric symptoms in patients with FTD. The search strategy included the following terms-"FTD and psychiatry," "FTD and behavioural disturbances," and "FTD and treatment". Pathophysiology of psychiatric symptoms in FTD is different from other types of dementia. Although drugs for Alzheimer disease appear to be ineffective for the treatment of psychiatric symptoms of FTD, preliminary evidence supports a possible usefulness of serotonergic antidepressants for these patients. Data are too scanty to draw definitive conclusions, but antidepressant treatment, particularly with serotonergic compounds, may improve psychiatric symptoms in patients with FTD. Large observational studies are needed to confirm this preliminary evidence, and a lot of effort and collaboration between neurologists and psychiatrists will be definitely crucial for future research of effective treatments for FTD.


Subject(s)
Frontotemporal Dementia/drug therapy , Frontotemporal Dementia/psychology , Antidepressive Agents/therapeutic use , Humans , Serotonin/metabolism
15.
J Affect Disord ; 224: 32-47, 2017 12 15.
Article in English | MEDLINE | ID: mdl-28089169

ABSTRACT

BACKGROUND: Among emerging treatments for depressive disorders several studies suggested that n-3 polyunsaturated fatty acids (n-3PUFAs) supplementation can be used. However, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) differ in terms of biochemistry, metabolism and therapeutic effects. Therefore, a clear picture of their specific and different role on affective disorders has not yet emerged. OBJECTIVES: To investigate the effects of n-3PUFAs on affective disorders including major depression, bipolar disorder and perinatal depression. METHODS: a comprehensive search on PUBMED, Medline and PsychINFO of all RCTs using n-3PUFAs patients with depressive symptoms published up to April 2016 was performed. We included trials that examined unipolar or bipolar disorder and trials that investigated depressive symptoms in relation to pregnancy. Trials were excluded if the depressive symptomatology was related to other primary organic diseases. RESULTS: 264 RCT studies were identified but only 36 met the inclusion criteria. First, it has been reported that n-3PUFAs supplementation might have clinical benefits on depressive symptoms. Second, EPA supplement, rather than DHA, seems to be more effective in treating major depression. Third, n-3PUFAs can have beneficial effects in bipolar depression but not in perinatal depression. CONCLUSIONS: there are only some evidence on the efficacy of n-3PUFAs in affective disorders especially to unipolar and bipolar depression not powered enough to confirm a therapeutic effect for affective disorder. Therefore, further studies with larger and more homogeneous samples, are required to confirm these effects.


Subject(s)
Dietary Supplements , Fatty Acids, Omega-3/therapeutic use , Mood Disorders/drug therapy , Adult , Bipolar Disorder/drug therapy , Depressive Disorder, Major/drug therapy , Docosahexaenoic Acids/therapeutic use , Eicosapentaenoic Acid/therapeutic use , Female , Humans , Male , Mood Disorders/prevention & control , Treatment Outcome
17.
Compr Psychiatry ; 69: 78-87, 2016 08.
Article in English | MEDLINE | ID: mdl-27423348

ABSTRACT

The assessment of schizotypy allows to identify people at risk to develop psychosis. For this purpose, psychometric tools have been developed, such as the Magical Ideation Scale (MIS). This scale investigates attenuated forms of thought transmission experiences, thought withdrawal and aberrant beliefs, related to positive schizotypy. This study aims at providing an Italian version of the MIS and its normative data in the general population from childhood to adulthood, being the first study evaluating subjects under 17year-old. The Italian MIS version was translated by three independent operators and administered to 1378 non-clinical participants, stratified into four age groups (i.e., 8-13, 14-17, 18-24 and 25-34). The unidimensionality of the scale was supported, and its internal consistency was satisfactory (i.e., ordinal Cronbach's αs ranging from 0.86 to 0.90 in different age groups), as well as test-retest reliability (i.e., 1-month ICC of 0.82 in a retested sub-sample). Normative data for the age groups were provided. Specific gender and age-related differences in MIS score were found, i.e. females scored higher than males in the 25-34 age group, which in general, as a group, scored lower than all the other age groups. This study provided evidence of reliability for the Italian version of the MIS in childhood and adolescence, for the first time, as well as in adulthood, showing specific gender and age effects in the early adult cohort.


Subject(s)
Schizotypal Personality Disorder/diagnosis , Adolescent , Adult , Age Factors , Child , Female , Humans , Italy/epidemiology , Male , Psychiatric Status Rating Scales , Psychometrics , Reproducibility of Results , Sex Factors , Translations , Young Adult
18.
Hum Psychopharmacol ; 31(5): 349-55, 2016 09.
Article in English | MEDLINE | ID: mdl-27400882

ABSTRACT

OBJECTIVE: The aim of this open-label naturalistic study was to assess clinical outcomes and the predictive value of duloxetine plasma levels in major depressive disorder in the elderly. METHODS: This naturalistic, open-label design involved 35 outpatients aged between 65 and 87 years. Duloxetine plasma levels were collected in 24 patients after the first month. Patients were evaluated using 21-item Hamilton Rating Scales for Depression, Hamilton Rating Scales for Anxiety, the Clinical Global Impression Severity, Mini Mental State Examination, Cumulative Illness Rating Scale, Barthel Index and Beck's Depression Inventory. RESULTS: Duloxetine plasma levels at T2 ranged from 4.9 to 201.9 ng/mL without a significant correlation between duloxetine dose and plasma levels. A significant improvement in mean 21-item Hamilton Rating Scales for Depression total scores at T2,T3, T4, T9 and T12 and a progressive significantly decrease of the mean Hamilton Rating Scales for Anxiety scores from T3 to T12 were observed. CONCLUSIONS: The levels of duloxetine in plasma do not correlate with a greater clinical improvement, indeed appear to adversely affect the improvement of the Beck Depression Inventory and Hamilton Rating Scales for Anxiety. This could be explained by an increase in side effects that may aggravate the discomfort felt by the patient. Copyright © 2016 John Wiley & Sons, Ltd.


Subject(s)
Depressive Disorder, Major/drug therapy , Duloxetine Hydrochloride/administration & dosage , Serotonin and Noradrenaline Reuptake Inhibitors/administration & dosage , Age Factors , Aged , Aged, 80 and over , Depressive Disorder, Major/physiopathology , Dose-Response Relationship, Drug , Duloxetine Hydrochloride/adverse effects , Duloxetine Hydrochloride/pharmacokinetics , Female , Humans , Male , Predictive Value of Tests , Psychiatric Status Rating Scales , Serotonin and Noradrenaline Reuptake Inhibitors/adverse effects , Serotonin and Noradrenaline Reuptake Inhibitors/pharmacokinetics , Treatment Outcome
19.
Int Clin Psychopharmacol ; 31(6): 347-52, 2016 11.
Article in English | MEDLINE | ID: mdl-27384739

ABSTRACT

Anxiety disorders are common, comorbid, and disabling conditions, often underdiagnosed and under-treated, typically with an early onset, chronic course, and prolonged duration of untreated illness. The present study aimed to explore the influence of sociodemographic and clinical factors in relation to onset and latency to treatment in patients with generalized anxiety disorder (GAD), panic disorder (PD), and obsessive-compulsive disorder (OCD). A total of 157 patients with a Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Text Revision (DSM-IV-TR) diagnosis of PD (n=49), GAD (n=68), and OCD (n=40) were recruited, and epidemiological and clinical variables were collected through a specific questionnaire. Statistical analyses were carried out to compare variables across diagnostic groups. PD, GAD, and OCD patients showed a duration of untreated illness of 53.9±81.5, 77.47±95.76, and 90.6±112.1 months, respectively. Significant differences between groups were found with respect to age, age of first diagnosis, age of first treatment, family history of psychiatric illness, onset-related stressful events, benzodiazepine prescription as first treatment, antidepressant prescription as first treatment, and help-seeking (self-initiated vs. initiated by others). Patients with GAD, PD, and OCD showed significant differences in factors influencing onset and latency to treatment, which may, in turn, affect condition-related outcome and overall prognosis. Further studies with larger samples are warranted in the field.


Subject(s)
Anxiety Disorders/psychology , Anxiety Disorders/therapy , Obsessive-Compulsive Disorder/psychology , Obsessive-Compulsive Disorder/therapy , Panic Disorder/psychology , Panic Disorder/therapy , Adult , Age Factors , Aged , Antidepressive Agents/therapeutic use , Anxiety Disorders/diagnosis , Female , Humans , Male , Middle Aged , Obsessive-Compulsive Disorder/diagnosis , Panic Disorder/diagnosis , Time-to-Treatment
SELECTION OF CITATIONS
SEARCH DETAIL
...